Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

A young man with an eating disorder had a life-threatening adrenal crisis due to an autoimmune condition, highlighting the need for better education on managing hormone treatments.

Early diagnosis and treatment of congenital adrenal hyperplasia are crucial to manage symptoms and prevent complications.

Different conditions affect how hair proteins assemble, and certain mutations can change their structure.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

This therapy effectively treats resistant alopecia areata with minimal side effects.

Balneophototherapy effectively treats ichthyosis linearis circumflexa but may need ongoing treatment due to short remission.

Hair absorbs alkali bromide salts and water, affecting its structure, with absorption decreasing at higher temperatures.

COVID-19 doesn't make alopecia areata worse.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Corin helps control salt and sweat release in sweat glands.

Allergen desensitization reduces hair loss severity in dust-mite allergic alopecia areata patients.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Both topical calcipotriol and narrowband UVB improved alopecia, but combining them didn't enhance the effect on hair loss severity, despite higher vitamin D3 levels.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

Ritlecitinib is effective for long-term treatment of severe alopecia areata.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Japanese patients with alopecia areata often have a higher BMI and consume more vitamin C, fruit, and retinol, which may affect their condition's development or severity.

People with Alopecia areata often have lower vitamin D levels, which may be linked to the severity of their condition.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.